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Abstract
New tools that allow dynamic visualization of molecular neural events are important for studying
the basis of brain activity and disease. Sensors that permit ligand-sensitive magnetic resonance
imaging (MRI) are useful reagents due to the non-invasive nature and good temporal and spatial
resolution of MR methods. Paramagnetic metalloproteins can be effective MRI sensors due to the
selectivity imparted by the protein active site and the ability to tune protein properties using
techniques such as directed evolution. Here we show that structure-guided directed evolution of
the active site of the cytochrome P450 BM3 heme domain (BM3h) produces highly selective MRI
probes with sub-micromolar affinities for small molecules. We report a new, high affinity
dopamine sensor as well as the first MRI reporter for serotonin, with which we demonstrate
quantification of neurotransmitter release in vitro. We also present a detailed structural analysis of
evolved BM3h lineages to systematically dissect the molecular basis of neurotransmitter binding
affinity, selectivity, and enhanced MRI contrast activity in these engineered proteins.
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INTRODUCTION
The exploitation of paramagnetic metalloproteins as magnetic resonance imaging (MRI)
contrast agents is a promising direction for molecular imaging. Unlike traditional
organometallic chelates, metalloproteins are amenable to protein engineering strategies that
tune biophysical properties and molecular interactions. Endogenous metalloproteins such as
ferritin already play a significant role in tissue and disease-specific MRI contrast
differences1, and ectopic expression has been shown to produce artificial contrast
enhancement. Protein-based contrast agents can also be delivered exogenously using
invasive or noninvasive means, even to the brain.4 Ligand-dependent MRI contrast agents
enable imaging of molecular events in the body, offering the possibility of improving on
traditional approaches to functional MRI, which monitor physiological events only via
changes in blood flow5. In the brain, metalloprotein-based probes that are engineered to
respond to neurochemicals could be particularly useful, by providing direct molecular
readouts associated with normal neural activity or dysregulation of chemical signaling in
disease6.
The bacterial cytochrome P450-BM3 heme domain (BM3h) is an attractive starting point for
MRI sensor design, as the protein can be modified to improve stability and alter substrate
specificity via directed evolution and rational design approaches. The active site of BM3h
possesses a hexacoordinate heme-bound paramagnetic iron center containing a labile axial
water molecule12, allowing the protein to act as an MRI contrast agent. In a recent report,
we showed that BM3h demonstrates longitudinal (T1) 1H MRI contrast enhancement that is
modulated by binding of cognate fatty acid ligands in the cavernous active site13. A
customized high-throughput optical screening method was developed to generate binding
isotherms by monitoring P450-Soret absorbance changes as a function of ligand
concentration (supplementary fig. 1)13. Using directed evolution, we altered ligand
specificity to provide BM3h-derived sensors exhibiting high affinity for dopamine (DA).
Five rounds of random mutagenesis and screening led to the isolation of variant BM3h-B7,
with >300-fold improvement in the dissociation constant (Kd) for DA (990 ± 110 μM to 3.3
± 0.1 μM; table 1, fig. 1b) and an 85% maximal change in the strength of the contrast agent
(longitudinal molar relaxivity, r1, an indicator of MRI contrast agent specific activity given
by the slope of the longitudinal relaxation rate 1/T1 vs. concentration) in response to DA
binding. Increases in DA affinity were accompanied by concomitant loss in fatty acid
binding; however, screening BM3h-B7 against other important neural markers revealed
considerable affinity for similar biogenic amines including norepinephrine (NE) and
serotonin (5HT, fig. 1a, 1b).13 Further improvements in DA specificity will assist
application of these sensors in the brain, especially in regions where competing ligands
might interfere with DA binding or complicate interpretation of contrast changes produced
by the sensors.
We hypothesized that broadly specific sensors such as BM3h-B7 might provide useful
starting points for continued directed evolution to generate further improvements in DA
selectivity and to create MRI sensors for other neurotransmitters, such as 5HT. The ability to
image DA is significant due to the importance of DA in learning, reward, and motor control
functions, as well as its role in several neurodegenerative diseases and addiction. 5HT is of
interest because abnormalities in 5HT signaling are implicated in depression and other mood
disorders. Here we demonstrate that the structural analysis of BM3h variants can guide
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directed evolution efforts. Targeting mutations to residues in the active site that directly
contribute to ligand binding has allowed us to generate highly selective BM3h MRI sensors.
We report DA sensors with improved affinity and ligand specificity, as well as the first
reported protein-based MRI sensor for 5HT, which demonstrates excellent specificity
combined with sub-micromolar affinity. We also show that mutations to the active site of
BM3h result in molecular MRI sensors with enhanced contrast effects and ligand-dependent
signal changes. Finally, we provide X-ray crystallographic data that elucidate the basis of
BM3h ligand binding, selectivity and T1 relaxivity changes. This work represents one of the
few systematic structural investigations of protein lineages derived from directed evolution
and demonstrates at the atomic level how mutations lead to altered ligand binding and MRI
contrast.
RESULTS
Structural basis of DA binding in evolved BM3h variants
In wild type and evolved BM3h variants, DA, 5HT and NE show binding behavior marked
by a red-shifted Soret band indicative of axial iron coordination by the neurotransmitter
(supplementary fig. 1). Structure-activity studies with DA homologues modified at the
amine and hydroxyl moieties identified the 2-amino group as responsible for this interaction
(supplementary fig. 2a and ref. 12). DA, 5HT and NE likely share similar binding
modalities, based on their related structures (fig. 1a) and the broad specificity observed for
BM3h-B7 and its progenitor BM3h-8C8 (fig. 1b). We predicted that improvements in
selectivity might be achieved with mutations focused to the protein active site. X-ray
crystallography was used to obtain the structures of the DA- and 5HT-bound proteins and
choose positions for saturation mutagenesis, which accesses amino acid substitutions that
are not accessible by random point mutagenesis. Ligand-bound structures were obtained by
co-crystallization in the presence of 2 mM DA or 5HT and show active site electron
densities that allow for unambiguous assignment of the neurotransmitter (supplementary fig.
3). A full summary of X-ray crystallographic data for BM3h-8C8 and BM3h-B7, as well as
other BM3h variants described below, can be found in supplementary tables 1 - 6.
BM3h is composed of two subdomains, an N-terminal beta-domain and an alpha helical-rich
subdomain that includes the heme-bound active site (supplementary fig. 4). The active site is
enclosed by several alpha helices, including the B’-helix (residues 73-82), I-helix (residues
252-282), active site capping F- and G-helices (residues 172-227), as well as several flexible
loops. In the presence of cognate fatty acid substrates, BM3h undergoes ligand-dependent
conformational changes, with pronounced movements in the F-, G- and I-helices, that are
important for the low-spin to high-spin iron transition and catalysis19. Conformational
heterogeneity observed among evolved BM3h variants is independent of neurotransmitter
binding, suggesting that binding in solution does not induce the same large-scale backbone
changes (see supplementary fig. 4 for a detailed discussion).
DA-bound BM3h-8C8 and BM3h-B7 structures (fig. 1c - 1f) confirm axial heme
coordination by the DA amine. In both variants, the backbone carbonyl of A330 acts as a
bifurcated hydrogen bond acceptor to the catecholic DA hydroxyls (fig. 1c, 1d). DA binding
is further stabilized by two networks of water molecules that form bridging hydrogen bonds
between the DA p-hydroxyl group (fig. 1c, 1f) and BM3h functional groups such as the
backbone carbonyl of L437, a heme proprionate, and the backbone amide nitrogen of A74.
Comparison of DA-bound structures and published BM3h structures suggests that similar
bound water networks are found in the protein active site even in the absence of ligands20.
Interactions between BM3h and DA hydroxyls and amine are, for the most part, independent
of acquired amino acid mutations. These interactions probably contribute to the low but non-
negligible DA affinity exhibited by wild type BM3h (Kd ~ 1 mM).
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BM3h-8C8 and BM3h-B7 share three active site mutations, T268A, I263A, and L75P (fig.
1b). Biochemical evidence suggests that the mutations located outside of the active site do
not make significant contributions to DA affinity improvements. Shortening of the T268
side-chain by mutation to alanine may prevent steric clash between the T268 Cγ and DA
ethylamine (fig. 1c - 1e). In the wild type protein, the T268 hydroxyl inserts into and bends
the P450 I-helix by hydrogen bonding to the backbone carbonyl of A264, disrupting i – i+4
hydrogen bonding. While the I-helix remains bent in T268A variants, we observe a rotation
of the I-helix between F261 and A264 (fig. 1e). This rotation may create an unfavorable
clash between I263 and F81 that is alleviated in subsequent generations by mutation I263A.
It is known that substrate-dependent I-helix rotations are important for enzymatic
catalysis,19 and others have observed similar I-helix rotations after mutating nearby residues
such as A26421.
L75P appears to improve hydrophobic packing of the DA catechol against the side-chain of
F87, which sits just above the heme. In wild type BM3h, the orientation of F87 is dictated
by the side-chain of L75. In BM3h-8C8, the L75P mutation allows F87 to swing away from
the ligand-binding pocket to accommodate the DA catechol in a tilted-T ‘π-stacking’
interaction (fig. 1d). L75 resides in the B’-helix, yet its mutation in BM3h-8C8 does not
significantly alter the protein backbone. However, in daughter variant BM3h-B7, mutation
F81L induces large-scale collapse of this helix into the active site (3.7 Å Cα - Cα change at
A74, fig. 1f). The comprehensive structural analysis of the BM3h-8C8/BM3h-B7 lineage
allows us to pinpoint at what point during evolution such large-scale backbone changes
occur. Had we limited X-ray crystallographic efforts to the endpoint BM3h-B7 variant, we
would likely have postulated that a helix- destabilizing L75P mutation was sufficient for this
movement. F81 packs against I263A, which, as noted above, assumes a slightly rotated
conformation due to mutation at T268A (fig. 1e, 1f). We conclude that the displacement of
the B’-helix of BM3h-B7 involves the subtle interplay of all 4 mutations. α-Helix
movements have been observed in other proteins engineered for ligand binding: evolution of
an aminoacyl-tRNA synthetase selective for p-bromophenylalanine included a proline-
induced α-helix rotation that resulted in significant restructuring of the enzyme active site24.
B’-helix collapse within BM3h-B7 allows an active site water to form a bridging hydrogen
bond between the amide nitrogen of A74 and DA p-hydroxyl (fig. 1f), contributing to the ~
3-fold (0.6 kcal/mol) increase in affinity over BM3h-8C8. Consistent with structure-activity
investigations (supplementary fig. 2), while hydrogen bonding to DA hydroxyls provides
some improvement in binding (~ 2–5 fold), it appears that the bulk of affinity increases in
these mutants results from optimized van der Waals packing resulting from side-chain
mutations.
Shared binding determinants contribute to overlapping DA and 5HT specificity in
BM3h-8C8
Evolved DA binders BM3h-B7 and BM3h-8C8 also bind 5HT, with Kd values of 18.6 ± 0.1
and 80 ± 8 μM, respectively (fig. 1b and table 1). To assess the origin of this overlapping
specificity, BM3h-8C8 was co-crystallized with 5HT (fig. 2 and supplementary table 1, 6).
An overlay of DA- and 5HT-bound BM3h-8C8 shows that 5HT occupies the same active
site cavity as DA and shares similar hydrophobic packing to active site side-chains (fig. 2b).
The exocyclic 5HT hydroxyl similarly hydrogen bonds to the backbone carbonyl of A330
and active site water networks. The indole nitrogen is oriented in such a way as to allow
direct hydrogen bonding to the backbone carbonyl of L437. This interaction may
compensate for the loss of hydrogen bonding to the DA p-hydroxyl (fig. 1c). Based on these
structures, no clear steric or hydrogen-bonding character substantially distinguishes either
ligand; the similar binding configuration observed for DA and 5HT accounts for the
relatively low specificity displayed by BM3h-B7 and -8C8.
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Active site directed evolution yields 5HT-selective BM3h variants
Based on the crystal structures of the DA- and 5HT-bound proteins and using BM3h-B7 as
the parent scaffold, we designed libraries in which mutations were focused around both
faces of the neurotransmitter aromatic ring. Each library consisted of saturation mutagenesis
at two positions to maximize diversity (1024 possible nucleotide sequences) yet maintain a
reasonable size for optical high-throughput titrations. Each library included site-saturation at
F87, which lies directly above the BM3h heme (fig 2) and has been shown to be important
for altering substrate specificity in evolved BM3h monooxygenases25. Three 2-site libraries
were constructed: F87+A74, F87+L75 and F87+T438 (fig. 2b). A74 and L75 (L75P in
BM3h-B7) are located in the B’-helix, and T438 is located in an adjacent loop. Screening
was performed as in our earlier work13, with slight modifications (supplementary Fig. 1d).
Briefly, libraries were transformed into E. coli and ~ 900 distinct colonies were expressed in
96-well blocks. Clarified lysate was distributed among three 96-well microtitre plates to
allow simultaneous positive/negative screening against DA, 5HT and NE. Variants
demonstrating improved binding or altered selectivity were isolated, purified to
homogeneity and analyzed for binding and ligand-dependent MRI activity.
No improvements in DA affinity or selectivity were acquired by these mutants. However, a
variety of BM3h variants were obtained with altered selectivity favoring 5HT. Clear trends
in 5HT binding affinity were observed at F87 with preference for aliphatic hydrophobic
amino acids (L is preferred, followed by V, A, and G; supplementary Fig. 5a). A single
mutation, F87L (this variant is denoted BM3h-3AE4; fig. 1b and table 1), was sufficient to
induce preference for 5HT (Kd of 3.9 ± 0.1 μM, a ~ 5-fold improvement compared to
BM3h-B7), with approximately 6-fold selectivity over DA (21.4 ± 1.3 μM) and 30-fold over
NE (91.3 ± 0.2 μM). A second mutation, T438L, further improved 5HT binding when
combined with F87L. Denoted BM3h-3DB10 (fig. 1b and table 1), this variant bound 5HT
with a Kd of 1.1 ± 0.2 μM and was ~ 45-fold selective with respect to DA and 190-fold with
respect to NE.
We next investigated whether 5HT-specific BM3h-3DB10 demonstrated ligand-dependent
relaxivity (r1) changes. Unfortunately, while BM3h-3DB10 exhibited 5HT-dependent
decreases in r1 (table 1), relaxivity observed in the absence of ligand (0.73 ± 0.05 mM−1 s−1)
was substantially less than wild type BM3h (1.23 ± 0.07 mM−1 s−1), limiting the overall
MRI signal change achievable by this sensor. The ligand-free Soret band of BM3h-3DB10 is
red-shifted from 419 nm to 422 nm (supplementary fig. 5b). This shift may reflect changes
in the local heme environment or even partial coordination of the heme iron by nearby
amino acids. Similar effects have been observed in BM3h mutants that introduce metal-
coordinating amino acids near the heme20. Iron coordination by residues within the active
site would compete with water occupancy at the heme, reducing r1.
Since wild type BM3h shows higher r1 than BM3h-3DB10, we asked whether 5HT-selective
mutations could restore affinity in the wild type background (Kd > 2.5 mM, table 1).
Mutation F87L produces a variant, BM3h-L4, with a Kd of 199 ± 1 μM (fig. 3a and table
1), augmenting 5HT binding ~ 13.5-fold. The subsequent addition of T438L (variant BM3h-
L6) further improves binding to 9.3 ± 1.3 μM. The increase in 5HT binding affinity
contributed by these two mutations is similar in scale to DA affinity enhancements achieved
by eight mutations in BM3h-B7. Moreover, BM3h-L6 is 80-fold selective over DA (Kd >
750 μM) and shows no binding to NE. Binding improvements due to T438L require F87L,
as the T438L single mutant, BM3h-L5, demonstrates no significant 5HT binding (table 1).
Relaxivities measured for BM3h-L4 and BM3h-L6 in the absence of ligand (r = 1.55 ± 0.14
mM−1s−1 and 1.44 ± 0.13 mM−1s−1, respectively, table 1) were greater than that of wild type
BM3h. These variants maintained ligand-sensitive relaxivity decreases of ~30% and ~78%,
respectively, upon addition of 2 mM 5HT.
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Cumulative improvements in BM3h-L6 5HT affinity suggested that binding could be further
enhanced by saturation mutagenesis at additional active site locations. Iterative saturation
mutagenesis has been used to improve enzyme activity on new substrates26 and
enantioselectivity27 by directed evolution. The small diversity (n = 32) of single-site
libraries is easily covered in one 96-well plate, and many single-site saturation libraries can
be screened in a couple of days. Six additional sites, L75, I263 and T268 (mutated in BM3h-
B7) as well as A74, A328, and L437 were chosen based on proximity to the bound ligand
(see fig. 1 and 2). From this, variant BM3h-2G9, mutated at T268S, was isolated (5HT – Kd
- = 3.3 ± 0.2 μM, fig. 3a). Subsequent saturation mutagenesis at remaining sites produced
BM3h-2G9C6 (F87L, T438L, T268S, L437Q) with sub-micromolar affinity for 5HT (Kd =
0.7 ± 0.2 μM) and > 250-fold selectivity over DA and NE (Kd = 198 ± 7 μM and Kd = 275
± 40 μM, respectively, fig. 3a and table 1). BM3h-2G9C6 maintains 5HT-dependent
decreases in MRI contrast and exhibits the highest ligand-free r1 (1.89 ± 0.02 mM−1s−1) of
any ferric P450-based MRI contrast agent we examined (table 1). 2G9C6 contains an
additional mutation, R51C, probably the result of polymerase error during library
construction. Reversion of this mutation had little impact on binding and relaxivity. It is
notable that 4 mutations within the active site improve 5HT binding by ~ 4000-fold without
negatively affecting T1 relaxation enhancement; indeed, the relaxivity is enhanced.
Moreover, unlike the more distributed mutations accumulated in BM3h-B7, the accumulated
active site mutations have minimal impact on protein stability (table 1 and supplementary
methods), which will facilitate further engineering7 and in vivo applications.
BM3h-based sensors detect serotonin release in cell culture
Screening BM3h libraries in lysate permits affinity selection in the context of potential
competitors derived from bacterial metabolism. However, in vivo application requires that
sensors be robust, sensitive, and specific in mammalian extracellular environments. To
demonstrate the utility of the evolved sensor to detect biologically-stimulated 5HT release,
we chose rat basophilic leukemia RBL-2H3 cells, a canonical model cell line for studying
Ca2+-mediated and ligand-stimulated 5HT secretion from cultured cells (fig. 4a). Long
thought to model some features of mucosal mast cell responses to stimuli, RBL-2H3 cells
have been previously used for direct imaging of 5HT fluorescence in secretory granules by
multiphoton microscopy, in a manner allowing quantification of intragranular 5HT
concentration.30 50 μM BM3h-2G9C6 protein exhibited a 9.7 ± 0.3% decrease in
longitudinal relaxation rate (R1) in cell supernatant extracted 15 min after stimulation with
2.5 μM ionomycin. Wild type BM3h showed negligible (0.9 ± 0.6%) change in R1 under
these same conditions. Using a ligand depleting binding model, we estimated that observed
BM3h-2G9C6 R1 changes correspond to a 5HT concentration of approximately 31.0 ± 1.0
μM in supernatants of ionomycin-treated cells, which corresponds well to estimates
obtained from measurements using a commercial colorimetric 5HT ELISA assay (fig. 4b).
Specificity of BM3h-2G9C6 for binding 5HT was further assessed by examining responses
to common 5HT precursors and metabolites (supplementary fig. 2b). Amino acid precursors
tryptophan and 5-hydroxytryptophan demonstrate no observable binding when incubated
with BM3h-2G9C6. Specificity is also observed against the monoamine oxidase-catalyzed
5HT degradation product 5-hydroxyindoleacetic acid as well as melatonin, a 5HT derivative
important for regulating circadian processes and found in high concentrations in the pineal
gland31. These data suggest that BM3h-2G9C6 will be useful for selective 5HT visualization
in biological settings.
Binding determinants in evolved BM3h 5HT sensors
Crystal structures of 5HT-selective variants BM3h-2G9 and BM3h-2G9C6 were determined
in order to help understand the origins of the observed binding specificity and MRI contrast
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effects (figure 3c - 3f). As in BM3h-8C8, the 5HT amine coordinates the heme iron;
however, 5HT does not interact with the backbone carbonyl of A330. Instead, 5HT occupies
a different orientation with the hydroxyindole group pointing towards the L437Q/T438L
loop (figure 3f). This alternate conformation is favored following introduction of two
leucine mutations, F87L and T438L, which also provide significantly improved 5HT affinity
(from > 2 mM in wild type BM3h to < 10 μM in BM3h-L6). As shown in figure 3c, these
side chains pack against each face of the 5HT aromatic ring system. Subsequent deletion of
the Cγ-methyl in T268S accommodates the 5HT ethylamine (fig. 3c and 3d). This mutation
parallels T268A in evolved DA variants. Hydrophilic 5HT functionalities form hydrogen
bonds to existing BM3h water networks that are often observed in the absence of ligand.20
In BM3h-2G9, for example, one water molecule bridges the indole nitrogen of 5HT and the
propionic acid side-chain of the heme cofactor. The exocyclic 5HT hydroxyl interacts with a
water network that splits the I-helix as well as interacts with the side-chain hydroxyl of
T268S (fig. 3d). Alanine was enriched at this location in earlier variants such as BM3h-8C8.
As the DA catechol occupies a different orientation in the BM3h active site (fig. 1c), there
was no selective advantage to maintain the side chain hydroxyl at position 268 during
evolution experiments for improved DA affinity.
The addition of L437Q in BM3h-2G9C6 improves binding to Kd ~ 700 nM (table 1). As
shown in figure 3e, the 5HT ring in BM3h-2G9C6 is rotated compared to BM3h-2G9,
possibly due to an alternative water network bridging the exocyclic hydroxyl and side-chain
of L437Q. The L437Q amide adopts an orientation that also promotes a dipole-dipole
interaction with the hydroxyindole ring. Improved hydrophobic packing and flexible
hydrogen bonding to various water networks may contribute significantly to 5HT binding
enhancements attributed to this mutation.
One striking feature of BM3h-2G9 and BM3h-2G9C6 is their remarkable selectivity for
5HT over DA and NE. Whereas BM3h-8C8 and BM3h-B7 have Kd values within an order
of magnitude for all three ligands, BM3h-2G9C6, for example, demonstrates > 250-fold
preference for 5HT over DA. As discussed above, broad specificity in BM3h-8C8 likely
results from shared binding determinants exploited by both DA and 5HT. In 5HT-specific
variants, the ligand occupies an alternate active site pocket (fig. 3f, see discussion). Our
attempts to isolate DA-bound BM3h-2G9C6 crystals were unsuccessful, but simple
modeling suggests that the DA ligand is too short to allow proper packing against T438L or
to form hydrogen bonds to water molecules exploited by 5HT (data not shown). In addition,
the lack of the indole nitrogen prevents DA hydrogen bonding to the propionic acid water
network as observed for 5HT.
Improved DA sensors by active site mutagenesis
Based on the success of 5HT sensor evolution, we asked whether active site-directed
saturation mutagenesis could also generate improved BM3h-derived DA sensors. Nine
active site residues in wild type BM3h were chosen for randomization: I263, A264, E267,
T268, T327, A328, T436, L437 and T438. As shown in fig. 3b and table 1, accumulating
single mutations (T268A, I263A, T438V and A328G) yielded a new variant, denoted
BM3h-9D7, with improved affinity (Kd = 1.3 ± 0.1 μM), ligand selectivity (5HT K = 70 ± 3
μM and NE K = 37 ± 1 μM) and relaxivity (1.31 ± 0.07 mM−1S−1) compared to BM3h-B7
and wild type BM3h.
In DA-bound BM3h-9D7 (fig. 5), the DA catechol ring is oriented towards the same active
site cavity as in BM3h-8C8 and BM3h-B7 (fig. 1). The ability of 5HT to share this binding
modality (fig. 2) may account for BM3h-9D7’s weaker ability to discriminate among
various neurotransmitters when compared to highly selective variants such as
BM3h-2G9C6. Nevertheless, the > 50 fold preference for DA over 5HT in BM3h-9D7,
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resulting from mutations in the ligand binding pocket, marks a substantial improvement in
selectivity when compared to BM3h-B7, which demonstrates only a ~ 5 fold preference for
DA over 5HT. This improvement in selectivity should translate well to in vivo imaging
experiments, where submicromolar concentrations of 5HT are typical.32
The BM3h-9D7 structure shows a different solution to DA-catechol binding than found in
BM3h-8C8 (fig. 5). In BM3h-9D7, wild type L75 is maintained; as such, the orientation of
F87 in the active site overlays well with the wild type protein (fig 5a). However, the side-
chain of A328, which packs against the opposite face of the DA catechol, is deleted by
mutation to glycine, allowing DA to rotate away from F87. An additional mutation in
BM3h-9D7, T437V, in close proximity to A328G, likely improves hydrophobic packing in
this region. Differences in catechol orientation may account for the 9-fold difference in DA
affinity between these two BM3h variants (fig 5b). In BM3h-9D7, DA takes on a more
favorable tilted-T (face-side) ‘π-stacking’ interaction with the phenyl ring of F87. Rotation
of the DA ring may also improve the co-planarity of catechol hydroxyls and A328 backbone
carbonyl. As no difference in hydrogen bonding is observed, the increases in BM3h-9D7
binding compared to BM3h-B7 and BM3h-8C8 likely result from improved van der Waals
interactions around the DA catechol ring.
Two active site mutations, T268A and I263A, were conserved in all DA-specific variants.
This observation led us to investigate whether any enhancements to ligand binding affinity
were conferred by the mutations outside of the active site in BM3h-B7 and -8C8.13 Each
round of mutagenesis and screening in the original BM3h-8C8 lineage identified at least one
active site mutation (fig. 1b) along with other mutations, not in the active site. Reverting
non-active site mutations in BM3h-8C8 (denoted BM3h-L75P) resulted in little change in
binding affinity and selectivity relative to the parent (table 1), underscoring the key role of
the active site mutations in enhanced neurotransmitter binding. As with BM3h-2G9C6 and
BM3h-9D7, however, the r1 of BM3h-L75P (1.64 ± 0.02 mM−1s−1) was substantially
improved by limiting mutations to the active site.
Structural insights into BM3h MRI relaxivity differences
Although 5HT- and DA-selective BM3h variants were not isolated on the basis of MRI
contrast properties, they exhibited substantially different relaxivities that corresponded to
trends in structural factors we identified by crystallography of BM3h sensor lineages. Key
determinants of r1 include solvent access to the heme, the geometry of the heme water
coordination (chiefly r, the iron-water proton distance), the exchange rate of bound water
molecules (TM), and the electronic relaxation time of the heme iron atom (TS). Two
structural features suggested that increased water access might help explain the improved
relaxivity of some of the mutant proteins. First, structures for unliganded forms of
BM3h-8C8, 2G9, 9D7, and 2G9C6 (r = 1.1, 1.27, 1.31, and 1.89 mM−1s−1, respectively)
showed regions of amorphous electron density near the heme (Supplementary fig. 6c - 6g),
possibly reflecting heme-associated water molecules20. These regions were larger for
variants with higher relaxivity. Second, we found evidence that higher r1 variants
demonstrate increased flexibility within certain regions of the active site, perhaps facilitating
exchange of water molecules into and out of the site. In BM3h-2G9C6, L437Q, E264, and
H266, show alternate conformations among crystallographic monomers that are not
observed in low-relaxivity variants (Supplementary fig. 7a - c); trends in increasing B-factor
at these locations are also observed (Supplementary fig. 7d - f). One region, the loop at the
top of the active site, contains both L437Q and T438L mutations found in BM3h-2G9C6
(Supplementary fig. 7i,j). Interestingly, this loop also flanks two of the three main channels
that allow water access to the BM3h active site and the side chain of L437Q is observed to
hydrogen bond to waters in these channels (fig 3e).
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To obtain additional information about structural determinants of BM3h relaxivity, we
measured the r1 of evolved variants as a function of proton NMR frequency from 0.01 – 42
MHz (Supplementary fig. 8), to obtain so-called nuclear magnetic relaxation dispersion
(NMRD) curves. Among the set of BM3h variants analyzed, r1 differences measured by
MRI at 200 MHz were more pronounced at lower field, and displayed sigmoidal transitions
(dispersions) at proton NMR frequencies of roughly 0.5 MHz. After correcting for a
modeled diamagnetic contribution33, NMRD data were well fit (R2 = 0.997 across mutants)
to a dipolar relaxation model consisting of a single inner sphere water (q = 1) and a single
low-spin iron (S = 1/2), with r, TM, and a field-independent TS as free parameters
(Supplementary fig 8, Inset). Estimates of r ranged from 2.6 – 3.0 Å, in good agreement
with high field NMR36 and EPR37 studies of P450 enzymes. Variations in TM (0.05 – 5 μs,
with shorter values corresponding to higher r1) and TS (0.5 – 0.8 ns) across mutants were
necessary to explain differences in the dispersion frequencies and asymptotic r1 values.
Although the TM values are probably only valid as order-of-magnitude estimates, the
observed trend is consistent with structural evidence that parameters affecting exchange of
bound waters might be particularly important for relaxivity changes in BM3h variants. The
NMRD results also suggest that orientation of bound water molecules (reflected by r) is
important for determining relaxivity, but the crystal structures do not have high enough
resolution to confirm or refute this possibility.
There was spectroscopic evidence that the BM3h variant with the lowest observed
relaxivity, BM3h-3DB10 (r1 = 0.73 mM−1s−1), experienced a decrease in the minor
population of S = 5/2 iron atoms observed in most P450 variants38. Other variants showed
virtually identical spectra to wild type BM3h (Supplementary fig. 6b), however, and the
relatively subtle changes in TS required for NMRD model fitting suggests that differences in
electronic relaxation properties are not very important for relaxivity determination among
protein variants. Collectively, the data argue that relaxivity enhancements in BM3h variants
are accessible by protein engineering, and that alterations to solvent interaction parameters
may be the primary mechanism by which mutations affect r1.
Discussion
We have shown that structure-guided iterative site-saturation mutagenesis within the active
site of P450 BM3h can significantly improve its performance as a ligand-responsive MRI
contrast agent. A few active site mutations dramatically increased DA and 5HT affinity to
levels within range of the physiological concentrations of these molecules in the brain. For
example, four mutations in BM3h-2G9C6 were sufficient to achieve submicromolar Kd
values for 5HT, representing an average affinity improvement of 10-fold for each mutation.
This sensor was capable of detecting 5HT release from mammalian cells in culture, and 5HT
concentration estimates obtained by MRI compared well with an MRI-independent 5HT
ELISA assay. It has been reported that deep brain stimulation can evoke the release of 5HT
in the dorsal raphe nucleus at concentrations approaching 1 μM.32 The binding affinity of
BM3h-2G9C6 (Kd ~700 nM) is suitable to detect 5HT under these conditions. In addition,
the high selectivity of BM3h-2G9C6 should minimize confounding signal changes due to
local concentrations of DA, which have repeatedly been shown to approach 10 μM in the
ventral striatum. On the other hand, the improved DA binding of BM3h-9D7 makes it well
suited for observing these levels of DA in the brain.39 We expect similar evolutionary
strategies can be applied for the production of BM3h-based sensors for a variety of
biologically important molecules.
The ability of BM3h to adapt to amphipathic ligands such DA and 5HT with only a few
active site mutations is impressive, especially bearing in mind that the cognate substrates of
the parent enzyme are long-chain aliphatic fatty acids. Important insights into the molecular
Brustad et al. Page 9
J Mol Biol. Author manuscript; available in PMC 2013 September 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
origins of improved ligand binding, with respect to these neurotransmitters, are provided by
careful analysis of crystal structures of a panel of ligand-bound BM3h variants. Amino acid
side-chain mutations almost exclusively improve hydrophobic packing against the aromatic
rings and ethylamine portions of bound DA and 5HT. On the other hand, exocyclic
hydroxyls and the 5HT indole nitrogen make use of backbone amides and active site water
molecules to form stabilizing hydrogen bonds. Improvements in these interactions by
directed evolution are marked by adjustments in hydrogen bonding networks rather than the
introduction of side chains that directly hydrogen bond to the ligand. Computational design
approaches that attempt to engineer side chain:ligand hydrogen bonds face an uphill battle
due to strict geometric requirements and limited sampling40. Evolution has arrived at an
elegant alternative solution by exploiting flexibility in water networks to accommodate
hydrophilic functionality in non-polar pockets. In addition, by making use of existing
protein-bound water networks rather than recruiting new ones, the energetic cost associated
with water rearrangement is likely very low41. Computational approaches that take water
into consideration may lead to considerable improvements in design.
While earlier BM3h evolution experiments using random mutagenesis and screening led to
significant enhancements in DA affinity, the resulting sensors demonstrated broad
specificity for structurally similar neurotransmitters including 5HT and NE13. Nonetheless,
these non-specific sensors offered important starting points for further evolution. By
focusing mutations to the ligand-binding pocket, we were able to isolate DA- and 5HT-
specific variants that showed marked selectivity relative to similar biogenic amines. For
example, BM3h-9D7 demonstrates a ~ 10 fold improvement in selectivity over 5HT when
compared to BM3h-B7. Tuning the local active site environment with the A328G mutation
provides an alternative hydrophobic packing solution that improves binding to the DA
catechol functionality while at the same time creating a less favorable setting for 5HT
recognition, which can occur at the same active site cavity (figure 2 and 5). The crystal
structures of highly specific 5HT sensors show an alternative conformation of the 5HT ring
with respect to more broadly specific DA- and 5HT-binding BM3h variants. By using
detailed structural information from a set of 5HT and DA-bound BM3h lineages, we are able
to pinpoint locations within the active site that are important for maintaining or altering
ligand binding geometry. Isolating active site mutations that favor alternative selective
binding geometries over orientations that can be shared by similar ligands may be a general
means to obtain highly selective sensors. Similar promiscuous protein function has been
suggested to be important in natural protein evolution, where basal levels of promiscuous
function (catalysis, substrate specificity etc.) that provide even a minimal advantage under
selective pressures may provide starting points for the evolution of completely new protein
function44. The evolution experiments for 5HT selectivity described here mimic this process
in a laboratory setting. However, by applying a structure-guided saturation mutagenesis
approach in the active site of BM3h, we are able to arrive at these solutions more rapidly
than through random mutagenesis.
We observe considerable improvements in other properties including thermostability and T1
relaxivity in the active site mutants, whereas continued random mutagenesis often led to
deterioration in MRI contrast induction. Random mutagenesis and screening more
accurately reflects natural protein evolution processes and arrives at similar binding
solutions to active site mutagenesis. However, additional accumulating mutations, while
neutral with respect to ligand binding, may prove detrimental to MRI sensor sensitivity.
Many of the sensors described here show enhanced longitudinal relaxivity, signifying that
MRI signal is a function of the protein sequence and therefore can be improved by
evolution. Indirect structural information provided by X-ray crystallography of a series of
BM3h variants suggests that increased flexibility in certain regions of BM3h that enhances
water access to the protein active site may contribute to these improvements. These results
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are supported by NMRD experiments that show that changes in water residence time at the
heme iron center correlate with differences in relaxivity properties. We have recently shown
that > 2.5-fold improvements in MRI signal can be obtained by swapping the ferric heme
center with a non-natural Mn3+-containing porphyrin45. We expect that combining such
alternative protein engineering strategies with contrast-enhancing directed evolution will
generate novel BM3h-derived MRI sensors with the potential to rival organometallic
chelates.
Material and Methods
Materials
Dopamine hydrochloride, neurotransmitter homologues, lysozyme, DNase, δ-amino
levulinic acid (δ-ALA) and buffers were purchased from Sigma-Aldrich. Serotonin
hydrochloride was from TCI America, and norepinephrine bitartrate was from ChemPacific.
Growth media such as Terrific Broth (TB) and Luria Broth (LB) were purchased from
Research Products International. Restriction enzymes and other enzymes used for cloning
were obtained from New England BioLabs. Oligonucleotide primers were from Integrated
DNA Technologies.
P450 general cloning and library construction
P450-BM3h variants were cloned into and expressed from a modified version of plasmid
pCWori, a derivative of plasmid pHSe-5. This vector contains an ampicillin resisitance
marker for plasmid maintenance, a pBR322 origin for plasmid replication and a
constitutively expressed copy of the lac repressor; IPTG inducible expression is controlled
by a lacUV5 promoter and two tandem copies of the tac promoter. PCR-amplified P450
gene products are generally cloned between 5′ BamHI and 3′ EcoRI restriction sites. To
facilitate protein purification, a terminal 6XHis coding sequence was engineered into
pCWori, just prior to the stop codon and EcoRI restriction site. An XhoI site was introduced
prior to the 6XHis sequence to permit cloning of His-tagged P450 BM3h variants.
P450 site-directed mutagenesis and site-saturation library construction was achieved by
assembling PCR fragments made from oligonucleotides containing the desired codon
mutation or a degenerate NNK (or for reverse primers, the reverse complement MNN;
where N = A,T,G,C, K = G,T and M = A,C) codon, which codes for all 20 amino acids and
the TAG stop codon. PCR fragments were assembled using either standard overlap
extension PCR or through restriction cloning using the Type IIS restriction enzyme, BsaI,
depending on convenience. For example, if two mutation sites were located close together in
the BM3h sequence, scarless restriction cloning with BsaI, which allows for tailored
overhang regions for ligation, proved preferable to overlap extension PCR48. In general,
both methods prove equally efficient for site-directed mutagenesis and library construction.
A detailed list of primers will be made available upon request.
P450 expression and purification
For expression, pCWori-cloned P450-BM3h variants were transformed into E. coli strain
BL21(DE3) and expression pre-cultures were grown up, overnight, at 37 °C in LB
supplemented with 100 μg/mL of ampicillin. 5 mL pre-cultures were used to inoculate 500
mL of TB medium supplemented with ampicillin. An iron-rich heavy metal supplement
(1000X = 50 mM FeCl3, 20 mM CaCl2, 10 mM MnSO4, 10 mM ZnSO4, 2 mM CoSO4, 2
mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, and 2 mM H3BO3) and 500 μM δ-ALA, a heme
biosynthetic precursor, were also added to media to improve protein yields. Expression
cultures were grown to mid-log phase (A600 ~ 0.5), with constant shaking, at 37 °C and
subsequently allowed to drop to room temperature before induction with IPTG at a final
Brustad et al. Page 11
J Mol Biol. Author manuscript; available in PMC 2013 September 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
concentration of 500 μM. Protein expression was carried out for 16 hours at room
temperature before harvesting.
Expression cultures were harvested at 6,000 × g for 10 minutes in a Beckman Coulter
Avanti J-25 centrifuge. Cell pellets were resuspended in 25 mL of buffer (25 mM Tris pH
8.0, 300 mM NaCl, 20 mM imidazole) supplemented with 0.5 mg/mL of hen egg white
lysozyme. Cells were incubated on ice for one hour before lysis by sonication. Clarified
lysate was loaded onto a HisTrap™ HP 5 mL Ni-NTA column (GE Healthcare) and, after
washing with low imidazole buffer, 6XHis-tagged P450 was eluted by increasing the
imidazole concentration to 165 mM. 6XHis purified protein was buffer-exchanged into 20
mM Tris, pH 8.0, by consecutive washing in an Amicon® Ultra centrifugal filter (Millipore)
to remove salt and imidazole. The protein was then further purified by anion exchange over
a HiTrap™ 5 mL Q HP column (GE Healthcare) and eluted by the gradient addition of 0
mM – 450 mM NaCl. Protein typically came off the column at ~ 250 mM NaCl. Purified
protein was exchanged into phosphate-buffered saline, flash frozen on dry ice and stored at
− 80 °C until needed. Proteins intended for crystallography were exchanged into low salt tris
buffer (20 mM tris, pH 8.0, 20 mM NaCl) over a Sephacryl™ 200 high-resolution size
exclusion column (GE Healthcare) prior to setting up crystal trays.
Preparing P450-BM3h library variants for high-throughput screening
Individual colonies from BM3h variant libraries were picked into 96-well expression blocks
containing 400 μL LB supplemented with ampicillin. Typically, 4 – 8 wells of each block
were reserved for control plasmids expressing BM3h variants with known neurotransmitter
affinities. These pre-cultures were allowed to grow to saturation, overnight at 37 °C. The
following day, using a Beckman MultiMek™ 96 automated liquid handling robot, 100 μL of
each pre-culture was transferred to a 96-well plate containing 100 μL of 50% glycerol for
storage at −80 °C for subsequent plasmid isolation and sequence interrogation. An
additional 100 μL of culture was inoculated into 1 mL of TB medium supplemented with
ampicillin and heavy metal supplement. For high-throughput lysate experiments, δ-ALA
was not provided to the cells due to an observed high background absorbance resulting from
excessive amounts of free heme in the lysates. Expression cultures were grown for 3 hours
at 37 °C prior to induction with 500 μM IPTG and overnight expression at room
temperature.
After overnight expression, cells were harvested at 3500 × g for 10 minutes. The medium
supernatant was discarded and cell pellets were subjected to 1 round of freeze-thawing at −
80 °C to facilitate cell lysis. Thawed cell pellets were resuspended in 1 mL of PBS
supplemented with 0.5 mg/mL hen egg white lysozme and 0.03 mg/mL DNase and
incubated at 37 °C for 2 hours. After lysis, cell debris was pelleted at 4500 × g for 15
minutes. 200 μL of clarified lysate was transferred to each of three 96-well microtiter plates
using an automated liquid handling robot. Individual plates were screened against DA, 5HT
or NE, respectively, (see below).
Neurotransmitter binding affinities
Prior to titration experiments, purified P450 concentrations were measured using a standard
CO binding assay. Neurotransmitter binding was monitored by differential absorbance
spectroscopy of the heme Soret band in the presence of ligand. Absorbance measurements
were taken at room temperature using a Tecan Infinite® M200 absorbance plate reader.
Prior to each experiment, protein and ligands were stored on ice in the dark. In a typical
experiment, 20 μL of a 10 fold concentrated ligand solution, in degassed PBS, was added to
180 μL of protein (~ 2 – 3 μM in PBS). Absorbance spectra were collected from 350 nm to
500 nM and the difference absorbance spectra at various ligand concentrations were
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obtained by subtracting absorbance scans in absence of ligand (i.e. substituting 20 μL of
PBS for ligand stock solution). Binding isotherms were generated by measuring the total
change in absorbance between the maxima (435 nm) and minima (415 nm) of each
difference absorbance spectra (δA435nm - δA415nm) at each ligand concentration. An
example of data obtained from these measurements is provided in supplementary fig. 1. The
apparent dissociation constant, Kd, the extrapolated maximal absorbance change, Amax, and
absorbance baseline, A0, were estimated by fitting binding isotherms to a non-linear ligand
depleting binding model, equation (1), using Matlab © (2011, The Mathworks, Inc.)
(1)
[PT] gives the total protein concentration and [ST] indicates the total added substrate
concentration.
High-throughput ligand titration experiments
For each series of titrations, 12 concentrated ligand stocks were prepared in degassed-PBS
and stored on ice. Typically, 3-fold serial dilutions, centered on the neurotransmitter KD for
the parent P450-BM3h variant, were found sufficient to span a generous range of ligand
concentrations, allowing sub-saturation, mid-point and saturation events to be observed. For
titrations, zero point measurements were taken, scanning 305 - 505 nm, in the absence of
ligand. Subsequently, 10 μL of the lowest concentrated ligand stock solution was added to
each well and the absorbance was measured again from 305 - 505 nm. This process was
repeated, iteratively, for each of the twelve serial stock solutions. This process was
performed for each of three duplicate plates to allow the co-screening of DA, 5HT and NE,
independently, for each protein variant.
The final concentration of protein in solution is decreased 1.6 fold by the addition of 12
portions of ligand; however, control experiments demonstrated that this small dilution of
protein in high-throughput screening does not significantly alter measured KD values.
Varying protein concentration from 0.5 μM to 5 μM produces results in less than 10%
changes in apparent KD. In general, we have noticed that KD values measured using this
methodology, in lysate, are consistently about 3-fold higher than those determined on the
same purified protein. This difference in ligand binding may be due to sequestration of the
ligand by components of the cellular milieu or by competition with other cellular factors.
To facilitate data analysis, a MATLAB script was developed for automated data processing
and fitting. This program baselines initial Soret band absorbance, generates difference
spectra for each ligand concentration along the titration series, calculates the absolute
maxima – minima for each difference spectrum, plots binding isotherms for each protein in
the 96-well plate, fits these data to a non-linear ligand depleting binding model (similar to
equation (1)) and prints goodness of fit statistics for each binding isotherm. The binding
model was slightly adjusted to compensate for the small changes in protein concentration
that occur upon each subsequent addition of ligand. It was found that the overall dilution
factor, under these conditions, scaled with substrate concentration such that:
(2)
Therefore adjusting for changes in protein concentration, equation (1) can be modified by
multiplying each [PT] quantity by this dilution factor. The MATLAB script used for these
experiments is freely available upon request and should prove useful for others looking to
automate similar high-throughput titration experiments.
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Depending on the desired screening outcome, those variants that displayed 2-fold or greater
improvements in binding for one neurotransmitter (e.g. 5HT) with concomitant increases in
selectivity against other molecules (e.g. NE and DA) were rescreened in replicate. The best
hits from each round of mutagenesis and screening were the expressed and purified as
described and analyzed for accurate binding statistics as well as MRI activity.
Protein Crystallization
Several P450-BM3h variants described in this work were crystallized by vapor diffusion. A
1:1 mixture of a 15 mg/mL protein stock in 20 mM Tris, pH 8.0, and mother liquor was
combined in 24-well sitting-drop plates (Hampton Research). Mother liquor compositions
depended on the protein variant and are provided in Supplementary table 6. Protein crystals
were grown in the absence or presence of ligand. In the ligand-bound conditions, DA or
5HT hydrochloride salts were dissolved at 100 mM concentrations in the presence of a two-
fold excess of ascorbic acid as a reductant to prevent oxidation of the ligand during
crystallization. A 1/50 fold dilution of neurotransmitter (2 mM final concentration) was
added to concentrated protein stocks just prior to setting up each crystal tray. In the absence
of reductant, protein crystals and solutions would turn a dark brown color over a period of
days indicating oxidation of the neurotransmitter. In the presence of reductant,
crystallization trays could be stored, in the dark, for over a period of weeks without any
visible substrate oxidation. Under most conditions, crystal growth occurs over the period of
5 – 7 days; however, growth times were significantly shorten by microseeding with shards
taken from these crystals. In addition, crystals grown under microseeding conditions grew
larger and diffracted with improved resolution.
X-ray data collection and protein structure determination
X-ray diffraction data was collected at the Stanford Synchotron Radiation Lightsource,
beamline 12-2 on a Dectris Pilatus 6M detector. Data were collected at 100K and
wavelengths for data collection are listed in Supplementary Table 1-5. Diffraction datasets
were integrated with XDS53 and scaled using SCALA54. Initial phases were determined
using molecular replacement against the wild type P450-BM3h structure taken from PDB
2IJ2, chain A20. When more than one structure of the same BM3h variant was solved (i.e. in
the presence or absence of ligand), models from one structured were used as molecular
replacement for sister structures. In these cases Rfree statistics were maintained from model
to model to prevent over-fitting of the X-ray data (see Supplementary Table 6). Molecular
replacement was accomplished using MOLREP software55, a component of the CCP4
crystallography software suite56. Refinement was accomplished with iterative cycles of
manual model building within COOT57 and automated refinement using REFMAC58 within
CCP4. Final cycles of REFMAC refinement included TLS parameters. Non-crystallographic
symmetry constraints were not utilized during refinement. Kicked omit maps were generated
using the ‘calculate maps’ feature of the PHENIX software suite for automated structure
determination59. Statistics for data collection and final protein structure models are given in
Supplementary Tables 1 - 5. Model quality was assessed using the ‘complete validation’ tool
included in the PHENIX software suite. Ramachandran outlier statistics, generated from this
analysis, can be found in Supplementary Table 6. Ramachandran outliers typically
constituted < 0.2 % of all residues, with favored Ramachandran representing > 96.6 % of all
residues. Outliers generally lie in a poorly structured loop connecting the P450-BM3 F and
G helices (residues 190 – 195). These residues are often missing or marked by poor density
in these and other P450-BM3 structures within the protein database. All protein structure
figures were generated using PyMol software (The PyMOL Molecular Graphics System,
Version 1.3, Schrödinger, LLC.).
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MRI longitudinal molar relaxivity measurements
Longitudinal molar relaxivity, r1, measurements of purified BM3h proteins were performed
as previously described with slight modifications. Briefly, 50 μL purified protein samples in
a linear range of concentrations were freshly prepared in PBS pH 7.4 with or without 1 – 2
mM 5HT. The samples were imaged in 384-well microtiter plate wells at ambient
temperature (23 °C) in a 4.7 T Bruker Avance MRI scanner with a 40 cm bore. T1-weighted
spin echo pulse sequences (TE = 10 ms, TR = 73 – 5000 ms with increasing averaging with
decreasing TR) were used to acquire a 2-mm slice through the each plate. Longitudinal
relaxation rates (R1) were fit to a single exponential from reconstructed image data using
custom routines implemented in Matlab (Mathworks).
Cell culture serotonin release assay
Adherent RBL-2H3 rat basophilic leukemia cells (ATCC CRL-2256) were grown in Eagle’s
Minimal Essential Medium (Lonza) supplemented with 15% (v/v) fetal bovine serum
(Invitrogen), 100 U/mL penicillin and 100 μg/mL streptomycin to 80 – 90% confluency in
75 cm2 flasks at 37 °C, 5% CO2. The cells were then incubated in complete medium with
freshly prepared 5HT at 0.25 mM for 6 hours. The flask was washed three times with 10 mL
Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO3, 2.3 mM CaCl2, 5.6 mM D-
glucose and 5 mM HEPES, pH 7.4) and then treated with 1 mL Locke’s buffer containing
either 2.5 μM ionomycin from a DMSO stock or DMSO alone (final DMSO concentration
0.1% v/v in both conditions) for 15 minutes at 37 °C, 5% CO2. The supernatant was
collected and aliquoted into a microtiter plate and mixed with either wildtype or 2G9C6
protein to a final concentration of approximately 50 μM. The microtiter plate was imaged by
T1-weighted MRI as for purified protein samples. 5HT concentrations were estimated from
R1 relaxation rates by fitting to a bimolecular equilibrium quadratic binding model with
depletion, essentially as previously described13. Aliquots of the same supernatants were then
assayed using a commercial colorimetric 5HT ELISA kit (IBL America, Minneapolis, MN),
following the manufacturer’s protocol.
Nuclear magnetic relaxation dispersion analysis
The longitudinal relaxation rates of purified BM3h solutions were measured at 25°C in the
range of 10 kHz – 42.49 MHz using a SpinMaster FFC2000 1T C/DC (Stelar s.r.l., Italy)
fast field-cycling nuclear magnetic resonance relaxometer. For T1 measurements at field
strengths greater than 12 MHz (0.281 T), sample magnetization equilibrated at the relaxation
field before cycling to 16.2 MHz (0.383 T) for measurement of the magnetization after
application of a 90°-flip-angle RF pulse. This process was repeated 15 times with the
relaxation time varied from 0.01 to approximately 4T1. For relaxation fields less than 12
MHz, the sample was “pre-polarized” at a field strength of 25 MHz (0.587 T) for
approximately 4T1 to compensate for diminished signal at lower fields.
Spin-lattice molar relaxivity, r1, of 1H in aqueous solutions of a paramagnetic metalloprotein
is modeled as the sum (equation 3) of diamagnetic, rd, and paramagnetic, rp, molar
relaxation rates,
(3)
where Rw is the background relaxation rate of the aqueous solvent. The term r1p is the molar
form of the Solomon and Bloembergen equations (equation (4) and (5)):
(4)
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(5)
In these equations, c is the molar concentration of paramagnetic ion; cw is the molarity of
water (55.5 M); T 1M is the relaxation time of water bound to the paramagnetic ion; q is the
number of water molecules bound in the ion’s first coordination sphere; r is the effective
proton-ion distance for all bound water; ωI and ωS are the Larmor precession frequencies of
proton nuclear spin, I, and the unpaired electron spin, S, respectively; γI is the 1H
gyromagnetic ratio; β is Bohr magneton; g is the free electron g-factor. The characteristic
correlation time Tc, of the two Lorentzian terms, is the sum of Tc = TM + TS + TR, where these
correlation times correspond to the bound water residence time, the frequency-independent
electronic relaxation time, and the rotational correlation time of the overall complex,
modeled with the Stokes-Einstein relation.
Prior work to estimate parameters governing proton relaxation in solutions of P450
homologues have been based primarily on temperature-dependent relaxation rate
measurements at high NMR field strengths (200 - 600 MHz), at which rotational effects are
minimal and the contribution of diamagnetic relaxation can be neglected. At the lower field
strengths interrogated by field cycling relaxometers, the rotational correlation time becomes
a significant contributor to solvent relaxation of metalloproteins, and therefore diamagnetic
relaxation effects must be considered. Best fits to 25°C BM3h NMRD profiles (generally R2
> 0.99) were achievable when the diamagnetic contribution to overall relaxation rates were
removed using “model free” parameters in a three-term Lorentzian expansion previously fit
to NMRD profiles obtained for apotransferrin33. Importantly, apotransferrin is a somewhat
larger ~ 84 kDa protein, and the use of parameters for other diamagnetic proteins of lower
molecular weight similar to BM3h was insufficient (R2 < 0.9) to obtain acceptable
parameter estimates using simple paramagnetic relaxation models based on the Solomon and
Bloembergen theory. It should therefore be noted that we consider these parameter estimates
to be useful for relative comparison of the mutants particularly under observation here.
Parameter estimates were obtained using a nonlinear least squares fitting regression with
scripts written in MATLAB. See the caption to Supplementary fig. 7 for additional details of
assumptions used in the fitting procedure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations used
MRI magnetic resonance imaging
DA dopamine
5HT serotonin (5-hydroxytryptamine)
NE norepinephrine
BM3h cytochrome P450-BM3 heme domain
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• Cytochrome P450-BM3 demonstrates ligand-dependent MRI contrast
enhancements.
• Directed evolution rapidly improves P450-BM3 affinity for dopamine and
serotonin.
• X-ray crystallography shows the structural basis of improved ligand binding.
• Broadly specific sensors show overlapping ligand orientations in the active site.
• Highly specific sensors use unique binding modalities to increase specificity.
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Figure 1. Directed evolution and structural characterization of broadly specific DA sensors
(a) Structures of dopamine (DA), serotonin (5HT) and norepinephrine (NE). (b) Color-coded
bar graphs show affinity constants (Ka) for DA, 5HT and NE of error-prone PCR BM3h-B7
lineage from Ref. 12. Bars correspond to: DA (blue, left), 5HT (red, middle) and NE (green,
right). We have set the Y-axis in units of log(mM−1); for reference to table 1, the 0 axis
would correspond to a dissociation constant (Kd) of 1 mM. Bar graphs descending below the
0 axis indicate dissociation constants that exceed 1 mM. Residues located in the active site
of BM3h are marked (*). Mutations identified by ** were included to improve protein
stability. Errors for Ka bar graphs are reported as standard deviations determined from a
minimum of three independent experiments. (c) DA (blue) bound to BM3h-8C8 (green).
Waters are shown as red spheres and dashed lines indicate hydrogen bonds. The exocyclic
hydroxyls of DA form hydrogen bonds to the backbone carbonyl of A330. (d) Active site
alignment of BM3h-8C8 + DA (green) and wild type BM3h (grey, from PDB:2IJ2).20
Mutation at L75P allows movement of F81 to accommodate the DA ring (blue). (e) Rotation
of the I-helix (shown by arrow) due to mutation at T268A. An alignment of the wild type
(grey) and BM3h-8C8 + DA (green) is shown. A dashed line marks the wild type hydrogen
bond between the side-chain of T268 and the backbone carbonyl of A264. The rotation of
the I-helix can be readily observed by comparing the Cα positions of wild type I263 and
I263A in BM3h-8C8. (f) Large scale movements in the B’-Helix upon mutation of F81 in
the BM3h-8C8 (green) to leucine in BM3h-B7 (orange). BM3h-B7 bound DA is shown in
blue.
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Figure 2. Shared binding modalities in broadly specific DA/5HT binder BM3h-8C8
(a) BM3h-8C8 bound 5HT (purple) shares interactions that are used for DA binding modes
observed in fig. 1. The exocyclic hydroxyl forms a hydrogen bond with the backbone
carbonyl of A330 as well as an existing water network. The indole nitrogen forms a
hydrogen bond to the backbone carbonyl of L437. Hydrogen bonds are shown by dashed
lines and waters by red spheres. (b) The aromatic rings of 5HT and DA point into the same
binding pocket towards A330. 5HT is shown in purple overlaid with DA, shown in blue. In
both cases the neurotransmitter amine coordinates the heme iron center.
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Figure 3. Directed evolution and structural characterization of highly specific 5HT and DA
sensors
(a-b) Color-coded bar graphs show affinity constants (Ka) for DA, 5HT and NE as described
in fig. 1. (a) 5HT-selective BM3h-2G9C6 lineage evolved using active site-directed
libraries. (b) DA-selective BM3h-9D7 lineage evolved using active site-directed libraries.
(c) 5HT (dark red) bound to BM3h-2G9 (green backbone). Active site mutations F87L and
T438L (orange), shown as sticks and van der Waals spheres, provide the hydrophobic
packing core that sandwiches the 5HT ligand. T268S is also shown; deletion of the Cγ
methyl group accommodates the 5HT ethylamine moiety. (d) A network of waters connects
the 5HT exocyclic hydroxyl and the side-chain of T268S. A 2nd network of waters links the
indole nitrogen and the propionic acid side-chain of the heme. (e) Crystal structure of
BM3h-2G9C6 (gold) bound to 5HT (pink). A slight rotation in the bound 5HT compared to
BM3h-2G9 (transparent ligand) is observed as a result of the L437Q mutation. An extensive
water hydrogen bonding network linking L437Q and 5HT is also shown (red spheres and
dashed lines). Arrows indicate 2 of the 3 main solvent channels in BM3h. (f) A comparison
of 5HT orientations in broadly specific BM3h-8C8 (green protein, purple 5HT) and
BM3h-2G9C6 (gold protein, pink 5HT). 5HT occupies an alternative pocket within the
BM3h active site in 5HT-selective BM3h-2G9C6. In panels b and d, waters are shown as red
spheres and dashed lines indicate hydrogen bonds. Errors for Ka bar graphs are reported as
standard deviations determined from a minimum of three independent experiments.
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Figure 4. BM3h-2G9C6 is a sensor for secreted 5HT in cell culture
(a) RBL-2H3 cells secrete 5HT in response to increases in intracellular Ca2+ concentration
(e.g. by treatment with ionomycin), which can then be observed by T1-weighted MRI of
aspirated treatment medium mixed with purified BM3h protein in microtiter plate wells. The
image illustrates an example contrast-adjusted T1-weighted spin echo scan (TE = 10 ms, TR
= 1221 ms) of a 2-mm slice of microtiter wells containing, left, DMSO-treated cell
supernatant or, right, ionomycin-treated cell supernatant, both mixed with BM3h-2G9C6 to
a final concentration of 50 μM. (b) Estimates of absolute 5HT concentration in aspirated
treatment medium from 80 – 90% confluent 75-cm2 flasks 15 minutes after treatment with
Locke’s buffer containing either 0.1% (v/v) DMSO or 2.5 μM ionomycin. Briefly, clarified
supernatant was either mixed with purified BM3h-2G9C6 and observed by T1-weighted
MRI or assayed for 5HT content using a commercial colorimetric ELISA kit. (c) Aliquots of
the same samples as in (b) were imaged by MRI after addition of 50 μM BM3h wild type
(WT) or BM3h-2G9C6 protein. Longitudinal relaxation rates (R1) of BM3h-containing
samples are expressed as −ΔR1/R1,0 = (R1,0 - R1,15)/R1,0 × 100%, where R1,0 and R1,15 are
the relaxation rates of Locke’s buffer containing BM3h protein and either DMSO or 2.5 μM
ionomycin before or after 15 minutes of exposure to cells, respectively. Errors are reported
as standard deviations determined from a minimum of three independent experiments.
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Fig. 5. Alternative dopamine binding in BM3h-9D7
(a) Active site alignment of BM3h-9D7 + DA (teal) and wild type BM3h (grey, from PDB:
2IJ2)20 shows no change in F87 orientation. (b) Active site alignment of BM3h-8C8 + DA
(green) and BM3h-9D7 + DA (teal). Differences in DA ligand orientation are due to
mutations at L75P (BM3h-8C8) or A330G (BM3h-9D7), which allow improved packing of
F87 against the DA catechol ring. Residue identities in parentheses represent mutations that
differ in BM3h-9D7 and BM3h-8C8.
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